1. The status of progress towards new TB vaccines Hassan Mahomed South African Tuberculosis Vaccine Initiative, University of Cape Town but also on behalf of the Aeras Global Tuberculosis Vaccine Foundation, Rockville, Maryland, U.S.A

2. Background Tuberculosis (TB) is a major global public health problem with 8.9 million new cases in 2004 affecting mainly Africa, South-East Asia and the Western Pacific (WHO). One third of the world’s population is estimated to be infected with the tuberculosis mycobacterium. Source: WHO report 2006: Global Tuberculosis Control

3. The Top 10 high burden TB countries CountryPopulation 1000’s All TB cases 1000’s TB cases per 100 000 1.India1 087 1241824168 2. China1 307 9891325101 3. Indonesia220 077539245 4. Nigeria128 709374290 5. South Africa47 208339718 6. Bangladesh139 215319229 7. Pakistan154 794281181 8. Ethiopia75 600267353 9. Phillipines81 617239293 10. Kenya33 467207619 Source: WHO report 2006: Global Tuberculosis Control

4. 2002: Most TB cases were in India and China The designations employed and the presentation of material on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. White lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2003 10 000 - 99 999 100 000 - 999 999 < 1 000 1 000 - 9 999 No estimate Number of cases 1 000 000 or more Asia 59% Africa 21% Global Tuberculosis Control. WHO Report 2003. WHO/HTM/TB/2004.331 Europe 10% India – 1.75 M Cases China – 1.33 M Cases

5. 25 to 49 50 to 99 100 to 299 < 10 10 to 24 300 or more No Estimate per 100 000 population Highest TB rates per capita are in Africa

6. TB and HIV 55% of South Africans with TB also have HIV. TB is the most common cause of death in people living with HIV. Those living with HIV have a 10% annual risk of contracting TB.

7. What is a vaccine? A vaccine is made from an infectious organism but modified either by weakening it or by taking a piece of it. This is then given either by injection or orally or by a novel method e.g. aerosol. The body’s immune response to this is intended to protect against infection and disease caused by the infectious organism itself.

8. Vaccine success stories Small pox eradication. Polio close to eradication. Also, measles, diphtheria, whooping cough and many others.

9. TB vaccination Bacille Calmette Guérin (BCG) has been around since the 1920s. It is the mostly widely used vaccination today (about 100 million doses in 2002). However, its efficacy is controversial. Nevertheless, there is broad consensus that it provides protection against severe forms of childhood TB. Unfortunately, there is growing concern that BCG can cause disease in HIV infected infants.

10. Prospects for new vaccines: approaches Replacement of BCG by a more potent pre-exposure vaccination inducing an immune response capable either of  complete elimination of all of the infecting organisms, or  reliable containment of persistent infection. Postexposure vaccination to boost immunity in individuals whose natural immune response has already been primed by infection or by BCG vaccination. Target in both cases: enhancement of BCG / natural immunity.

11. Aeras Global TB Vaccine Foundation Is an: International non-profit Product Development Partnership (PDP) funded by foundations (Bill & Melinda Gates) and government (DANIDA, CDC, NIH) that partners with industry and academia to develop high risk, high volume, low profit but desperately needed new TB vaccines. Mission: To develop new TB vaccines and ensure their availability to all who need them Goals: - To obtain regulatory approval and ensure supply of a new TB vaccine regimen within 7-10 years - To introduce 2 nd generation vaccines with improved product profiles and efficacy against latent TB in 9-15 years

12. A Promising Pipeline of Candidates Recombinant BCG  rBCG30(well tolerated in phase I)Aeras  Endosome escaping rBCGMPI/VPM  Aeras 412Aeras Recombinant fusion proteins in adjuvant  Mtb72f/M72 fusion (well tolerated in phase I)GSK  Ag85B::ESAT6 SSI/TBVAC  Ag85B::10.4 fusionSSI/Aeras Vectored vaccines  rMVA-Ag85A (well tolerated in many Phase I)Oxford  rAd35-Ag85A::Ag85B::TB-Y fusionAeras/Crucell  Oral Shigella dsRNA Aeras Bold type indicates Aeras support

13. TB vaccine candidates currently in human trials MVA85A (University of Oxford, UK) rBCG30 (St Louis University, US) Mtb72F (Corixacorp, US) Hybrid-1 (85B-ESAT6) (SSI, Denmark)

14. The role of the community Community advocacy for new TB vaccines Increase community knowledge about the value of vaccines. Participate in research Community Advisory Boards. Support research initiatives but also monitor study processes. Particularly look after participant interests.

15. Site development South African Tuberculosis Vaccine Initiative – Worcester/ Boland trial site India – Palamaner/ Institute for Population Health and Clinical Research, Bangalore EDCTP - Uganda and/or Kenya and/or Senegal Infrastructure, skills development, epidemiological baseline studies. Professional Development Programme

16. Critical Success factors Community Advocacy Promising candidates Basic science development capacity Clinical Trial Field Site infrastructure Demonstrated phase 1 and 2 safety including for those infected with HIV. Demonstrated efficacy Large scale production capacity Affordability Distribution infrastructure Health care infra-structure

17. Conclusions There is a high global TB burden. The existing vaccine, BCG has variable efficacy. A number of new TB vaccines are coming through the “pipeline”. The Aeras pipeline aims to produce a successful vaccine by 2012. The community has a crucial role to play in supporting the development of a new TB vaccine. By 2015, we will hopefully have in use a new, affordable and effective TB vaccine.

18. Acknowledgements Aeras Global TB Vaccine Foundation (Dr L Geiter) Dr T Hawkridge (SATVI) and other staff members of the team.